tetano
Editor, Senior Moderator
Crit Care Clin
. 2022 Jul;38(3):491-504.
doi: 10.1016/j.ccc.2022.03.003. Epub 2022 Mar 25.
Role of Acute Thrombosis in Coronavirus Disease 2019
Derek V Gibbs[SUP] 1 [/SUP], Satya S Shreenivas[SUP] 2 [/SUP], Kristin M Hudock[SUP] 3 [/SUP]
Affiliations
Abstract
Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are prone to venous, cerebrovascular, and coronary thrombi, particularly those with severe coronavirus disease 2019 (COVID-19). The pathogenesis is multifactorial and likely involves proinflammatory cascades, development of coagulopathy, and neutrophil extracellular traps, although further investigations are needed. Elevated levels of D-dimers are common in patients with COVID-19 and cannot be used in isolation to predict venous thromboembolism in people with SARS-CoV-2. If given early in hospital admission, therapeutic-dose heparin improves clinical outcomes in patients with moderate COVID-19. To date, antithrombotics have not improved outcomes in patients with severe COVID-19.
Keywords: Anticoagulation; COVID; Coronary thrombus; D-dimer; NETs; Thrombosis.
. 2022 Jul;38(3):491-504.
doi: 10.1016/j.ccc.2022.03.003. Epub 2022 Mar 25.
Role of Acute Thrombosis in Coronavirus Disease 2019
Derek V Gibbs[SUP] 1 [/SUP], Satya S Shreenivas[SUP] 2 [/SUP], Kristin M Hudock[SUP] 3 [/SUP]
Affiliations
- PMID: 35667739
- DOI: 10.1016/j.ccc.2022.03.003
Abstract
Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are prone to venous, cerebrovascular, and coronary thrombi, particularly those with severe coronavirus disease 2019 (COVID-19). The pathogenesis is multifactorial and likely involves proinflammatory cascades, development of coagulopathy, and neutrophil extracellular traps, although further investigations are needed. Elevated levels of D-dimers are common in patients with COVID-19 and cannot be used in isolation to predict venous thromboembolism in people with SARS-CoV-2. If given early in hospital admission, therapeutic-dose heparin improves clinical outcomes in patients with moderate COVID-19. To date, antithrombotics have not improved outcomes in patients with severe COVID-19.
Keywords: Anticoagulation; COVID; Coronary thrombus; D-dimer; NETs; Thrombosis.